Patents by Inventor Abdul HAKKIM R.

Abdul HAKKIM R. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineering of DNASE enzymes for manufacturing and therapy
    Patent number: 11840712
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: December 12, 2023
    Assignee: Neutrolis, Inc.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • Engineering of DNASE enzymes for manufacturing and therapy
    Patent number: 11578314
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (DTL2), DNASE1-LIKE 3 Isoform 1 (DTL3), DNASE1-LIKE 3 Isoform 2 (DTL3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: February 14, 2023
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • ENGINEERING OF DNASE ENZYMES FOR MANUFACTURING AND THERAPY
    Publication number: 20220162575
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (DTL2), DNASE1-LIKE 3 Isoform 1 (DTL3), DNASE1-LIKE 3 Isoform 2 (DTL3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Application
    Filed: February 10, 2022
    Publication date: May 26, 2022
    Inventors: Tobias A. FUCHS, Abdul HAKKIM R.
  • METHODS OF USING DNASE1-LIKE 3 IN THERAPY
    Publication number: 20210299178
    Abstract: The present disclosure provides D1L3 enzymes having complete or partial C-terminal deletions of the basic domain (BD), which have substantially enhanced chromatin-degrading activity. In various aspects, the invention provides chromatinase enzyme therapy, which is optionally provided by delivering polynucleotides encoding chromatinases such as D1L3, or by delivering host cells expressing and secreting the same.
    Type: Application
    Filed: June 10, 2021
    Publication date: September 30, 2021
    Inventors: Tobias A. FUCHS, Abdul HAKKIM R.
  • Methods of using DNASE1-like 3 in therapy
    Patent number: 11058724
    Abstract: The present disclosure provides D1L3 enzymes having complete or partial C-terminal deletions of the basic domain (BD), which have substantially enhanced chromatin-degrading activity. In various aspects, the invention provides chromatinase enzyme therapy, which is optionally provided by delivering polynucleotides encoding chromatinases such as D1L3, or by delivering host cells expressing and secreting the same.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: July 13, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • ENGINEERING OF DNASE ENZYMES FOR MANUFACTURING AND THERAPY
    Publication number: 20210207114
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Application
    Filed: March 23, 2021
    Publication date: July 8, 2021
    Inventors: Tobias A. FUCHS, Abdul HAKKIM R.
  • Manufacturing and engineering of DNASE enzymes for therapy
    Patent number: 10988746
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: April 27, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • DNASE1-LIKE 3 AND ITS USE IN THERAPY
    Publication number: 20200323917
    Abstract: The present disclosure provides D1L3 enzymes having complete or partial C-terminal deletions of the basic domain (BD), which have substantially enhanced chromatin-degrading activity. In various aspects, the invention provides chromatinase enzyme therapy, which is optionally provided by delivering polynucleotides encoding chromatinases such as D1L3, or by delivering host cells expressing and secreting the same.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Inventors: Tobias A. FUCHS, Abdul HAKKIM R.
  • MANUFACTURING AND ENGINEERING OF DNASE ENZYMES FOR THERAPY
    Publication number: 20200115690
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Application
    Filed: November 27, 2019
    Publication date: April 16, 2020
    Inventors: Tobias A. FUCHS, Abdul HAKKIM R.